2159 Stock Overview
Mediwelcome Healthcare Management & Technology Inc., an investment holding company, provides integrated healthcare marketing solutions in the People’s Republic of China.
Mediwelcome Healthcare Management & Technology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.17|
|52 Week High||HK$2.28|
|52 Week Low||HK$0.83|
|1 Month Change||0.86%|
|3 Month Change||11.43%|
|1 Year Change||-46.82%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-69.13%|
Recent News & Updates
Calculating The Intrinsic Value Of Mediwelcome Healthcare Management & Technology Inc. (HKG:2159)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mediwelcome Healthcare...
Some Investors May Be Worried About Mediwelcome Healthcare Management & Technology's (HKG:2159) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
|2159||HK Healthcare||HK Market|
Return vs Industry: 2159 exceeded the Hong Kong Healthcare industry which returned -68.4% over the past year.
Return vs Market: 2159 underperformed the Hong Kong Market which returned -23.3% over the past year.
|2159 Average Weekly Movement||9.1%|
|Healthcare Industry Average Movement||8.3%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.7%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2159 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 2159's weekly volatility (9%) has been stable over the past year.
About the Company
Mediwelcome Healthcare Management & Technology Inc., an investment holding company, provides integrated healthcare marketing solutions in the People’s Republic of China. It offers medical conference, patient education and screening, and marketing strategy and consulting services; and contract research organization services consist of patient’s recruitment and clinical data collection services. The company also operates a mobile application to provide internet hospital services comprising online follow up consultation to the physicians’ existing patients and e-prescription services.
Mediwelcome Healthcare Management & Technology Fundamentals Summary
|2159 fundamental statistics|
Is 2159 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2159 income statement (TTM)|
|Cost of Revenue||CN¥614.76m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.023|
|Net Profit Margin||0.66%|
How did 2159 perform over the long term?See historical performance and comparison
Is 2159 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2159?
Other financial metrics that can be useful for relative valuation.
|What is 2159's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2159's PE Ratio compare to its peers?
|2159 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 2159 is expensive based on its Price-To-Earnings Ratio (43x) compared to the peer average (11.1x).
Price to Earnings Ratio vs Industry
How does 2159's PE Ratio compare vs other companies in the Hong Kong Healthcare Industry?
Price-To-Earnings vs Industry: 2159 is expensive based on its Price-To-Earnings Ratio (43x) compared to the Hong Kong Healthcare industry average (17.3x)
Price to Earnings Ratio vs Fair Ratio
What is 2159's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||43x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2159's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 2159 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2159's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2159's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2159's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Mediwelcome Healthcare Management & Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mediwelcome Healthcare Management & Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Mediwelcome Healthcare Management & Technology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Mediwelcome Healthcare Management & Technology competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Mediwelcome Healthcare Management & Technology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2159 has a high level of non-cash earnings.
Growing Profit Margin: 2159's current net profit margins (0.7%) are lower than last year (4.9%).
Past Earnings Growth Analysis
Earnings Trend: 2159's earnings have declined by 41.7% per year over the past 5 years.
Accelerating Growth: 2159's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2159 had negative earnings growth (-77.9%) over the past year, making it difficult to compare to the Healthcare industry average (34.8%).
Return on Equity
High ROE: 2159's Return on Equity (1.8%) is considered low.
Discover strong past performing companies
How is Mediwelcome Healthcare Management & Technology's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2159's short term assets (CN¥275.3M) exceed its short term liabilities (CN¥57.3M).
Long Term Liabilities: 2159's short term assets (CN¥275.3M) exceed its long term liabilities (CN¥15.9M).
Debt to Equity History and Analysis
Debt Level: 2159 is debt free.
Reducing Debt: 2159 has not had any debt for past 5 years.
Debt Coverage: 2159 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 2159 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Mediwelcome Healthcare Management & Technology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2159's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2159's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2159's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2159's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2159 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Liang Wang (46 yo)
Mr. Liang Wang serves as the Chief Executive Officer at Mediwelcome Healthcare Management & Technology Inc. and has been its Executive Director since September 18, 2019. Mr. Wang co-founded Mediwelcome Gro...
Experienced Management: 2159's management team is considered experienced (2.8 years average tenure).
Experienced Board: 2159's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mediwelcome Healthcare Management & Technology Inc.'s employee growth, exchange listings and data sources
- Name: Mediwelcome Healthcare Management & Technology Inc.
- Ticker: 2159
- Exchange: SEHK
- Founded: 2000
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: HK$234.000m
- Shares outstanding: 200.00m
- Website: https://www.mediwelcome.com
Number of Employees
- Mediwelcome Healthcare Management & Technology Inc.
- Parkview Place
- 10th-12th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.